AOXG Stock Overview
A specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Aoxing Pharmaceutical Company, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.01 |
| 52 Week High | US$0.018 |
| 52 Week Low | US$0.004 |
| Beta | 0 |
| 1 Month Change | 61.29% |
| 3 Month Change | -39.39% |
| 1 Year Change | 63.93% |
| 3 Year Change | 233.33% |
| 5 Year Change | -27.01% |
| Change since IPO | -99.94% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| AOXG | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 42.9% | 0.5% | -2.1% |
| 1Y | 63.9% | 2.3% | 21.3% |
Return vs Industry: AOXG exceeded the US Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: AOXG exceeded the US Market which returned 21.3% over the past year.
Price Volatility
| AOXG volatility | |
|---|---|
| AOXG Average Weekly Movement | 82.1% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AOXG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AOXG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Zhenjiang Yue | axzyen.icm.cn |
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People’s Republic of China. The company’s principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain.
Aoxing Pharmaceutical Company, Inc. Fundamentals Summary
| AOXG fundamental statistics | |
|---|---|
| Market cap | US$3.81m |
| Earnings (TTM) | -US$1.46m |
| Revenue (TTM) | US$30.11m |
0.0x
P/S Ratio0.0x
P/E RatioIs AOXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AOXG income statement (TTM) | |
|---|---|
| Revenue | US$30.11m |
| Cost of Revenue | US$7.17m |
| Gross Profit | US$22.94m |
| Other Expenses | US$24.40m |
| Earnings | -US$1.46m |
Last Reported Earnings
Mar 31, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did AOXG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/12 22:19 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2017/03/31 |
| Annual Earnings | 2016/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aoxing Pharmaceutical Company, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elemer Piros | Rodman & Renshaw, LLC |